{"name":"Emergent BioSolutions","slug":"emergent","ticker":"EBS","exchange":"NYSE","domain":"emergentbiosolutions.com","description":"Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.","hq":"Gaithersburg, MD","founded":0,"employees":"900","ceo":"Joe Papa","sector":"Biodefense / CDMO / Public Health","stockPrice":8.27,"stockChange":0.42,"stockChangePercent":5.35,"marketCap":"$428M","metrics":{"revenue":742900000,"revenueGrowth":-23.6,"grossMargin":49.4,"rdSpend":53200000,"netIncome":52600000,"cash":205400000,"dividendYield":0,"peRatio":8.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"BioThrax patent cliff ($1.1B at risk)","drug":"BioThrax","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"NuThrax patent cliff ($500M at risk)","drug":"NuThrax","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"oncology","drugs":[{"name":"AV7909 Formulation 1","genericName":"AV7909 Formulation 1","slug":"av7909-formulation-1","indication":"Other","status":"phase_1"},{"name":"AV7909 Formulation 2","genericName":"AV7909 Formulation 2","slug":"av7909-formulation-2","indication":"Other","status":"phase_1"},{"name":"CYFENDUS","genericName":"CYFENDUS","slug":"cyfendus","indication":"Other","status":"marketed"},{"name":"ACAM2000","genericName":"ACAM2000","slug":"acam2000","indication":"Other","status":"marketed"},{"name":"ACAM2000 Smallpox Vaccine","genericName":"ACAM2000 Smallpox Vaccine","slug":"acam2000-smallpox-vaccine","indication":"Prevention of smallpox","status":"phase_2"},{"name":"AIGIV","genericName":"AIGIV","slug":"aigiv","indication":"Other","status":"phase_2"},{"name":"AV7909 Formulation 3","genericName":"AV7909 Formulation 3","slug":"av7909-formulation-3","indication":"Other","status":"phase_1"},{"name":"AV7909 Formulation 4","genericName":"AV7909 Formulation 4","slug":"av7909-formulation-4","indication":"Other","status":"phase_1"},{"name":"Ad4-PA-1","genericName":"Ad4-PA-1","slug":"ad4-pa-1","indication":"Other","status":"phase_1"},{"name":"Ad4-PA-GPI-1","genericName":"Ad4-PA-GPI-1","slug":"ad4-pa-gpi-1","indication":"Other","status":"phase_1"},{"name":"Blood sample collection","genericName":"Blood sample collection","slug":"blood-sample-collection","indication":"Other","status":"marketed"},{"name":"Sample Collection","genericName":"Sample Collection","slug":"sample-collection","indication":"Other","status":"marketed"},{"name":"UV-4B 10 mg","genericName":"UV-4B 10 mg","slug":"uv-4b-10-mg","indication":"Other","status":"phase_1"},{"name":"Vaccination with ACAM2000","genericName":"Vaccination with ACAM2000","slug":"vaccination-with-acam2000","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AVA","genericName":"AVA","slug":"ava","indication":"Prophylaxis of anthrax infection in persons at high risk of exposure","status":"marketed"}]}],"pipeline":[{"name":"AV7909 Formulation 1","genericName":"AV7909 Formulation 1","slug":"av7909-formulation-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AV7909 Formulation 2","genericName":"AV7909 Formulation 2","slug":"av7909-formulation-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVA","genericName":"AVA","slug":"ava","phase":"marketed","mechanism":"AVA is an anthrax vaccine that stimulates the immune system to produce antibodies against anthrax toxins, providing protection against infection by Bacillus anthracis.","indications":["Prophylaxis of anthrax infection in persons at high risk of exposure","Post-exposure prophylaxis following confirmed or suspected anthrax exposure"],"catalyst":""},{"name":"CYFENDUS","genericName":"CYFENDUS","slug":"cyfendus","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ACAM2000","genericName":"ACAM2000","slug":"acam2000","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ACAM2000 Smallpox Vaccine","genericName":"ACAM2000 Smallpox Vaccine","slug":"acam2000-smallpox-vaccine","phase":"phase_2","mechanism":"ACAM2000 Smallpox Vaccine works by stimulating an immune response to the smallpox virus.","indications":["Prevention of smallpox"],"catalyst":""},{"name":"AIGIV","genericName":"AIGIV","slug":"aigiv","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AV7909 Formulation 3","genericName":"AV7909 Formulation 3","slug":"av7909-formulation-3","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AV7909 Formulation 4","genericName":"AV7909 Formulation 4","slug":"av7909-formulation-4","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ad4-PA-1","genericName":"Ad4-PA-1","slug":"ad4-pa-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ad4-PA-GPI-1","genericName":"Ad4-PA-GPI-1","slug":"ad4-pa-gpi-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Blood sample collection","genericName":"Blood sample collection","slug":"blood-sample-collection","phase":"marketed","mechanism":"Blood sample collection is a diagnostic procedure, not a drug with a pharmacological mechanism of action.","indications":[],"catalyst":""},{"name":"Sample Collection","genericName":"Sample Collection","slug":"sample-collection","phase":"marketed","mechanism":"Sample Collection is not a drug but a process used in clinical trials and medical testing to gather biological samples for analysis.","indications":[],"catalyst":""},{"name":"UV-4B 10 mg","genericName":"UV-4B 10 mg","slug":"uv-4b-10-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vaccination with ACAM2000","genericName":"Vaccination with ACAM2000","slug":"vaccination-with-acam2000","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Emergent BioSolutions Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"The company reported net sales of $1.1 billion for the full year 2023, up 12% from 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-11-21","type":"deal","headline":"Emergent BioSolutions Announces Collaboration with the U.S. Department of Health and Human Services to Develop and Manufacture Next-Generation Anthrax Vaccine","summary":"The collaboration aims to develop and manufacture a next-generation anthrax vaccine.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Emergent BioSolutions Receives FDA Approval for BioThrax for Use in Adults and Children","summary":"The FDA approved BioThrax for use in adults and children.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBLQXlIRE16OHpNcnNHTFVrUHp5Y0VsRnQ5UXNBb1Q4d25FR3c4ekpVWk80b3pDQ0dnZXBOMEMzc0U4amFMZmFOc0dyRk1pWlE0?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Emergent BioSolutions Inc. (EBS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Emergent BioSolutions Inc. (EBS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"earnings","source":"simplywall.st","summary":"Emergent BioSolutions (EBS) One Off Loss Clouds Return To Profitability Narrative - simplywall.st","headline":"Emergent BioSolutions (EBS) One Off Loss Clouds Return To Profitability Narrative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQNjk0emZsY2ZYRGpQTjNKaUZsallvc0RyRHkxa1ZFTU9JRTRtYzdBUjVtcjNLa3ZfMkZVZEhCa1ZBc0ljNkVZSDBfODJ4ekpIVXpDVzRiUGZ0eTVOVGVsZUM4dVBPSndMZnlJZ0c2OEl5SUFhMUZoUW1HMGtDcF9XMU1EY2NienE5aU9hMUF3QzhzaUlxNEFwWjVaS0bSAaQBQVVfeXFMTjVrTU9Vb1pORThHVWFSNm1Md3FYajVQNE1RanVWM3hOLUp0eVdUMUszN3JKZXVaYTBxQ2pLVjNwanFfaTZDcjd2V3RlRlBjTGF2R3BIeEhKNElRX2xlLW5penRDYTg3UjZNNndQTGV6c2hQMVhJaHgxOHVzZlljdEVuN0pYeUo3X0labEsyNHdjcGVDNkZHdWRkQzNiQV9LNG4zd0Y?oc=5","date":"2026-02-04","type":"pipeline","source":"Law Street Media","summary":"Emergent Biosolutions, Insider Trading, and the Gemba Shuffle - Law Street Media","headline":"Emergent Biosolutions, Insider Trading, and the Gemba Shuffle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNN0FQcjdnYjl6Sm01aTV2Y1BWSFdPdnBGWVdxdWF2WUZwbllpVE8yOTVJLVo3LWNwQXdueWRrVFdBdklxRTlRQXE3N1RLSC1jazhUY05ZVXRkbE5hX2hZd0ljSE9RMWJtcE1IdGJzZ2FndzBULWUwMnFWRlJNR2xCSWJpVHZIZlZXd2tGd3VPeDY5T0xZc0ZvaEZHNjBRS1o3UUNOczgtT2I4WUNl?oc=5","date":"2025-11-14","type":"pipeline","source":"BioWorld News","summary":"Invivyd, Emergent and Armata drive infectious disease stock recovery - BioWorld News","headline":"Invivyd, Emergent and Armata drive infectious disease stock recovery","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-02","type":"earnings","source":"simplywall.st","summary":"Emergent BioSolutions (EBS): Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results - simplywall.st","headline":"Emergent BioSolutions (EBS): Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQa3R5TzNVMXhSQ09UNmZGVlFHb0JIcUVGc3p1bkJ2cVhFWEVNSGZtcm1xbFQtcDJGRzRzS1lKV1prNS05MjJ4WVpBTEw1VWhKaGMyMFBPaTZ2dWxjalc2M1hFdGhwWldKSVJOcXFldVV3R2FsOVd6c1Rwc0l2NVNEYW5xVmtaWFlUSFFWZzZtWXJqeW1TNmJSZEYzUEd5X3NTcUsxTXczTXo?oc=5","date":"2025-08-12","type":"pipeline","source":"The Business Journals","summary":"300 new jobs headed to Bayview manufacturing plant - The Business Journals","headline":"300 new jobs headed to Bayview manufacturing plant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1MUTVNTF9fZG5TTzRmTng4bTd0ODEyX0o3YTFyeXdab2xlM1dfMmVIVnptSmliT25vc1NCTDlQTFozbC1KSmdLajNWTU00ei1zY0RfRl9tNHNsRk9pTHJ5WUVfWjZMN3d4Mmc?oc=5","date":"2024-08-15","type":"pipeline","source":"qz.com","summary":"Mpox Vaccine Stock Who Emergency - qz.com","headline":"Mpox Vaccine Stock Who Emergency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNa2w3U0FYSGMyUERxczVqQmxXcENacnJKRE1MN0w0c2theDQ5Q0RGVE90VHVLbzZERkVaT3Y5RllsSEFKWGI4djRFVVNOdWk1V0lZejBIQmJZcXpDNjZ4N3lYWHRpbG85dnZZMmpQVWxVb01ncFVwWU03V09JTy0wZ2JCZTFveDg?oc=5","date":"2024-02-21","type":"pipeline","source":"Drug Delivery Business","summary":"Narcan nasal spray maker Emergent BioSolutions has a new CEO - Drug Delivery Business","headline":"Narcan nasal spray maker Emergent BioSolutions has a new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWkNuU1JjUDlOVk1aVTFMbjh6elhXbFFXanlFQ3BzVWtkSWlCaTJReHQzalhSRGU4NENucjVfeTdVek9OdTZNQmJaWVZTMm1GSE56VDJhRnJjU25FQ01oZ0hLNmF5dWVEbzMxeDVlMWZNZFJPZkJwZDVWcGs0NGwzWmJFQy00R3hNZXFJMTFyTDNBcTEybDVRREpDbw?oc=5","date":"2022-11-09","type":"pipeline","source":"Investor's Business Daily","summary":"Biotech Bloodbath: Why One Of These Four Plummeted 34% - Investor's Business Daily","headline":"Biotech Bloodbath: Why One Of These Four Plummeted 34% - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQOG1raTduT2RVSlNkZmdqTDFqM05Sb1dlLThVMnFFMGtCRkRkaUgwak1EQzhOQkprMDVTNE55MC1MSUhrbFRtOFhKeHotUFE2cHB6TkdBSElyMmNMcjcwTy1VN2JHTHhMYTBwWXpMREdSb3VSN3JIT1JIR3UybGxpQkgxa01QWEl2WG1DNWU5VVR4ekFVQUJ0WHc3N29yUmxXdjlDTEY0SEdRWXJrZTZXWG5hazNhV2JQWjBUT0tobmhmbFpianREVUFHaV9JRWlRYXc?oc=5","date":"2022-06-06","type":"deal","source":"reuters.com","summary":"J&J gives notice to terminate Emergent manufacturing deal for COVID vaccine - reuters.com","headline":"J&J gives notice to terminate Emergent manufacturing deal for COVID vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOdFNrb2dreE01QVVodVZxZTVtM2JaZVBWdDlOZzlObGgtaVhONDBJQ0JDMVdsdzF1emhEcmR2NVN3YVdVa28wTVdVdmdNY2IwdHZIWm5WWDZLYm9LNGNsQXRsXzNTTmY3XzRnWWZwS0F0anI0NGxrSjk2QXZyQXhoM3dxSmQ4OUtISUtodg?oc=5","date":"2022-05-19","type":"pipeline","source":"Barron's","summary":"Monkeypox Case Reported in U.S. Emergent BioSolutions Makes a Vaccine. - Barron's","headline":"Monkeypox Case Reported in U.S. Emergent BioSolutions Makes a Vaccine. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE1TeUtKNWNKMXlnUWVsbWRHV21IWXVMNUJ6R0NlWllRZkVoU25ZRlFIRmNILWZEYlpITjVVTG0tMHVldmNLcFFHYTJ5cWE?oc=5","date":"2021-09-14","type":"pipeline","source":"The Motley Fool","summary":"Emergent BioSolutions - EBS - Stock Price & News - The Motley Fool","headline":"Emergent BioSolutions - EBS - Stock Price & News","sentiment":"neutral"}],"patents":[{"drugName":"BioThrax","drugSlug":"anthrax-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"NuThrax","drugSlug":"anthrax-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":15,"phaseCounts":{"phase_1":7,"marketed":6,"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bavarian Nordic","Valneva SE","DynPort Vaccine Company LLC"],"therapeuticFocus":["Biodefense","Public Health"],"financials":{"source":"sec_edgar","revenue":742900000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":742900000,"period":"2025-12-31"},{"value":1043600000,"period":"2024-12-31"},{"value":1043600000,"period":"2024-12-31"},{"value":1049300000,"period":"2023-12-31"},{"value":1049300000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":53200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":52600000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1318600000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.27,"previousClose":7.85,"fiftyTwoWeekHigh":14.06,"fiftyTwoWeekLow":4.02,"fiftyTwoWeekRange":"4.02 - 14.06","fiftyDayAverage":9.68,"twoHundredDayAverage":9.46,"beta":2.36,"enterpriseValue":784701248,"forwardPE":2.8,"priceToBook":0.82,"priceToSales":0.58,"enterpriseToRevenue":1.06,"enterpriseToEbitda":3.76,"pegRatio":0,"ebitda":208900000,"ebitdaMargin":28.1,"freeCashflow":205387504,"operatingCashflow":170600000,"totalDebt":583699968,"debtToEquity":111.7,"currentRatio":5.01,"returnOnAssets":5.3,"returnOnEquity":10.5,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":2,"targetMeanPrice":12,"targetHighPrice":12,"targetLowPrice":12,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.9,"institutionHeldPercent":81.2,"sharesOutstanding":51644495,"floatShares":46818975,"sharesShort":8875813,"shortRatio":7.71,"shortPercentOfFloat":17.2,"epsTrailing":0.93,"epsForward":2.99,"revenuePerShare":13.89,"bookValue":10.03,"officers":[{"age":69,"name":"Mr. Joseph C. Papa Jr., M.B.A., R.Ph.","title":"CEO, President & Director"},{"age":61,"name":"Mr. Richard S. Lindahl M.B.A.","title":"Executive VP & CFO"},{"age":54,"name":"Ms. Coleen  Glessner","title":"Executive Vice President of Quality, Ethics & Compliance"},{"age":57,"name":"Mr. Paul A. Williams","title":"Senior Vice President of Products Business"},{"age":null,"name":"Mr. Simon C. Lowry M.D.","title":"Chief Medical Officer and Head of Research & Development"},{"age":44,"name":"Ms. Jessica  Perl","title":"Senior VP, Corporate Secretary & General Counsel"},{"age":null,"name":"Ms. Michelle  Pepin","title":"Senior VP & Chief Human Resource Officer"},{"age":null,"name":"Ms. Stephanie  Duatschek","title":"Chief Global Strategy & Franchise Development Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-irhome#node/150","website":"https://www.emergentbiosolutions.com","phone":"240 631 3200"}}